Clinical Trial

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study with repeated doses of AP1189. The study population will consist of patients with idiopathic membranous nephropathy (iMN) and severe proteinuria who are on ACE inhibitor or angiotensin II receptor blocker treatment.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-06-30; most recent amendment 2026-03-04.
Trial Details
NCT Number NCT04456816
Lead Sponsor SynAct Pharma Aps
Conditions Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy
Enrollment 23 participants
Start Date 2020-08-31
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-06